НовостиBenzingaSatellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback Benzinga 2026.11.06 12:02 (GMT+0) Открыть на Benzinga Другие новости